RapidPlan software in generating clinically acceptable plans in a semi-automated manner for 5-field IMRT prostate treatments. Statistical guidance on exclusion of outliers appears somewhat conservative -inclusion of all available good quality plans should improve the scope and robustness of the model. The results of section 2 showed however some important differences, especially on 3D margins for volumes with variable sections and small structures (<12 cm3), and the automatic positioning of the isocenter in complex structures. Minor discrepancies were identified on the conformation of the beams and jaws, the automatic contouring, and calculation of the volume of a structure showed less variation.
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1 Oncology Institute of Southern Switzerland, Medical Physics, Bellinzona, Switzerland 2 Humanitas Clinical and Research Center, Radiotherapy and Radiosurgery Dept, Italy Purpose/Objective: To evaluate the performance of a knowledge-based DVH estimation constraints, namely RapidPlan, for optimising volumetric modulated arc therapy (RapidArc) applied to advanced lung cancer and to low risk prostate carcinoma patients. Materials and Methods: Two sets, one for lung and one for prostate cases, each of 27 previously treated patients, were selected to configure and train models for the estimation of dose-volume constraints to use in the optimization process. The models were subsequently validated on the same sets of 27 plans each (closed-loop) and on further two sets each of 25 patients not used for the training (open-loop). The two site groups differ mainly in the homogeneity of the characteristics: -Advanced lung cancer group: in-homogeneous dose prescription (50-70 Gy), wide variety of target volumes (67-1193 cm 3 ), two partial arc geometry -Low risk prostate group: homogeneous dose prescription (78 Gy), modest variability of target volumes (80-421 cm 3 ), single full arc geometry Analysis was based on DVH and statistics comparison between the RapidPlan and the original clinically accepted plans. Second endpoint was the evaluation of the pass-fail analysis for the two groups of plans based on consolidated criteria as following. For lung cases: D 99% >95%(90%) and D 1% <107% for CTV(PTV); mean<20Gy for ipsilateral, mean<15Gy and V 20Gy <20% for contralateral lung; D 1cm3 <45Gy to spine; V 45Gy <30% and V 50Gy <20% for heart; D 1cm3 <70Gy and V 30Gy <30% for oesophagus. For prostate cases: D 99% >95% and D 1% <107% for PTV; V 70Gy <10%, V 60Gy <40% and V 50Gy <50% for rectum; V 70Gy <30% and V 60Gy <50% for bladder; D max <50Gy for femoral heads. In the pass-fail analysis, the rate of criteria not fulfilled was reduced in the lung patients group from 11% to 7% in the closed-loop and from 13% to 10% in the open-loop studies; in the prostate patients group it was reduced from 4% to 3% in the open-loop study. Conclusions: Plans were optimised using a knowledge-based model showed dosimetric improvements when compared to the original benchmark data, particularly in the sparing of organs at risk. The data suggests that the new engine is
